<DOC>
	<DOCNO>NCT00382252</DOCNO>
	<brief_summary>RATIONALE : Radiofrequency ablation use high-frequency , electric current kill tumor cell . Diagnostic procedure , PET scan CT scan , may help doctor measure patient 's response treatment . PURPOSE : This clinical trial study PET scan CT scan see well work evaluate response treatment patient undergoing radiofrequency ablation lung metastasis .</brief_summary>
	<brief_title>PET Scan CT Scan Evaluating Response Patients Undergoing Radiofrequency Ablation Lung Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine accuracy positron emission tomography ( PET ) CT scan measuring response 3 month radiofrequency ablation ( RFA ) patient lung metastasis . Secondary - Determine agreement observer analyze PET/CT scan result . - Determine outcome patient . - Determine false-positive rate false-negative rate PET/CT scan 1 3 month patient . - Determine optimal time obtain negative PET scan . - Determine sensitivity , specificity , positive predictive value , negative predictive value PET/CT scan 1 3 month . - Determine morbidity associate RFA . - Determine disease-free survival RFA factor predict recurrent disease patient . OUTLINE : This multicenter study . Patients undergo positron emission tomography ( PET ) CT scan baseline . Patients undergo radiofrequency ablation ( RFA ) lung metastasis . PET/CT scan repeat 1 week , 1 month , 3 month RFA . After completion RFA , patient follow clinical examination conventional scan 6 , 9 , 12 month . PROJECTED ACCRUAL : A total 80 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cancer Radiologically suspect pulmonary metastasis May confirm histologically specific marker Less 6 lesion Lesions &lt; 40 mm Prior positron emission tomography show 1 hyperfixation ( standard uptake variable &gt; 3 ) level lesion treat Lesions must attach next major mediastinal structure Radiofrequency ablation plan treatment PATIENT CHARACTERISTICS : Life expectancy &gt; 6 month No uncontrolled medical condition , include follow : Psychiatric condition Infection Coronary insufficiency New York Heart Association class IIIIV heart disease No serious condition No contraindication general anesthesia Not pregnant nursing PRIOR CONCURRENT THERAPY : At least 30 day since prior participation investigational study At least 30 day since prior chemotherapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>lung metastasis</keyword>
</DOC>